key: cord-0009981-695yvdcr
authors: Czerkinsky, Cecil; Anjueie, Fabienne; McGhee, Jerry R.; Geoige‐Chundy, Annie; Holmgren, Jon; Kieny, Marie‐Paule; Fujiyashi, Kohlaro; Mestecky, Jiri F.; Pierrefite‐Carle, Valérie; Rusk, Carok; Sun, Jia‐Bin
title: Mucosal immunity and tolerance: relevance to vaccine development
date: 2006-04-28
journal: Immunol Rev
DOI: 10.1111/j.1600-065x.1999.tb01339.x
sha: 83857755a980a9e03e17a3c65f233231c1d4ef68
doc_id: 9981
cord_uid: 695yvdcr

Summary: The mucosal immune system of mammals consists of an integrated network of lymphoid cells which work in concert with innate host factors to promote host defense. Major mucosal effector immune mechanisms include secretory antibodies, largely of immunoglobulin A (IgA) isotype, cytotoxic T cells, as well as cytokines, chemokines and their receptors. Immunologic unresponsiveness (tolerance) is a key feature of the mucosal immune system, and deliberate vaccination or natural immunization by a mucosal route can effectively induce immune suppression. The diverse compartments located in the aerodigestive and genitourinary tracts and exocrine glands communicate via preferential homing of lymphocytes and antigen‐presenting cells. Mucosal administration of antigens may result in the concomitant expression of secretory immunoglobulin A (S‐IgA) antibody responses in various mucosal tissues and secretions, and under certain conditions, in the suppression of immune responses. Thus, developing formulations based on efficient delivery of selected anti‐gens/tolerogens, cytokines and adjuvants may impact on the design of future vaccines and of specific immunotherapeutic approaches against diseases associated with untoward immune responses, such as autoimmune disorders, allergic reactions, and tissue‐damaging inflammatory reactions triggered by persistent microorganisms.

The mucous membranes covering the aerodigestive and the urogenital tracts as well as the eye conjunctiva, the inner ear and the ducts of all exocrine glands are endowed with powerful mechanical and physicochemical cleansing mechanisms that degrade and repel most foreign matter. In addition, a large and highly specialized immune system protects these surfaces and thereby also tbe body interior against potential insults from the environment. In a healthy human adult, this local immune system contributes almost 80% of all immunocytes. These cells are accumulated in or in transit between various mucosal organs and glands and together they form tbe mucosa-associated lymphoid tissue (MALT), the largest mammalian lymphoid organ system.

The MALT has three main functions: 1) to protect the mucous membranes against colonization and invasion by potentially dangerous microbes encountered; 2) to prevent uptake of undegraded antigens including foreign proteins derived from ingested food and commensal microorganisms; and 3) to prevent the development of harmful immune responses to these antigens if they do reach the body interior. At variance with tbe systemic immune apparatus, which functions in a normally sterile milieu and often responds vigorously to invaders, the MALT guards organs that are replete with foreign matter. It follows that upon encounter with this plethora of anligenic stimuli, tbe MALT must ignore such antigens, (5r economically select appropriate effector mechanisms and regulate their intensity to avoid bystander tissue damage and immunological exhaustion. Since this system cannot discriminate between pathogenic microorganisms on the one hand, and innocuous matter, such as dietary matter and commensal microorganisms, on tbe other, it is likely to recognize all foreign peptides. Elucidating the mechanisms that determine whether recognition of such diverse antigens will result in active immunity, immune suppression or ignorance, will have a major impact in the development of effective mucosal vaccines against infectious and inflammatory diseases.

Although the immune apparatus is remarkably diverse, there is strong evidence that certain types of immune responses take place and are basically restricted to certain anatomic locations witbin tbe body. The MALT represents a well-known example of such a compartmentalized immunological system. As opposed to tbe central and peripheral lymphoid organs, the MALT contains inhomogeneously distributed B and T cells whose phenotype, repertoire, developmental origin, secretion products and hence probably also function are different. First, the prime immunoglobulin isotype produced and assembled in mucosal tissues is secretory immunoglobulin A (IgA), which is only present in trace amounts in the intravascular compartment. Further, and although major species differences have been observed, non-conventional lymphocytes rarely seen in the spleen and peripheral lymph nodes are encountered at appreciable frequency in different mucosal locations, e.g. a/p TCR+CD4-CD8-cells, Y/5 TCR^CD4 CD8 a+CD8 p-and y/S TCR+CD4-CD8 a-CD8 p-T cells in the gut epithelium. The antigen receptor repertoire is also different in each location. Tbus, self-reactive T cells are detected among murine intestinal intraepithelial a/|i and 7/8 TCR"^ T lymphocytes. Furthermore, in contrast to the T and B lymphocytes found in central and peripheral lymphoid organs, certain 7/8 and a/p T cells found in the mucosa, and presumably also mucosal CD5+ B cells, do not depend on the thymns or bone marrow for their development, respectively. In addition to divergent lineages that are driven to different organs by tissue-specific homing receptors, local selection mechanisms may he important in the diversifi-cation of mucosal immune responses. Selection may be exerted by local antigens, antigen-presenting cells (APCs) whose function varies in each anatomical location, cytokines, chemokines and cell-matrix interactions, thus leading to the expansion and maintenance of some clones, whereas others are diluted out or deleted. Thus, by its cellular composition, and through the compartmentalization of its afferent and efferent limbs, the MALT functions essentially independently of the systemic immune apparatus.

Although most infectious microorganisms colonize or enter the host through mucosal membranes, it is the systemic immune system which has been tbe focus of most vaccine research. Aside from the ease of their administration, an important advantage of mucosal vaccines is the theoretical possibility of inducing both mucosal and systemic immune responses, while the reverse does not hold true. Since specific humoral immune defense is provided by both serum and hy secretory antibodies, predominately of the IgA isotype, tbat are selectively transported into external secretions, most vaccines considered for further improvement or development should ideally induce both systemic and mucosal responses.

Equally important to host immune defense is the capacity of MALT to promote specific immunological unresponsiveness (tolerance) after natural or deliberate mucosal exposure to a variety of antigens. This form of tolerance is considered as a major adaptive immune defense mechanism whereby we avoid developing harmful immune responses against the plethora of dietary and airborne antigens encountered each day.

Thus, from a theoretical standpoint, the possibility of manipulating the mucosal immune system towards positive immunity and/or tolerance appears extremely attractive w-hen considering strategies aimed at protecting the host from colonization or invasion by microbial pathogens but also to prevent and/or to modulate the development of potentially harmful immunological reactions against the same pathogens and also against certain self antigens and allergens. Such considerations should finally bring mucosal vaccines to center stage in vaccine development.

Adaptive effector mechanisms in mucosa! immune defense Three major adaptive effector mechanisms participate in the immune defense of mucosal surfaces. Secretory antibody formation and antigen-specific cell-mediated cytotoxicity are the primary mechanisms involved in antimicrobial defense and act primarily but not exclusively in the epitbellutn of all mucosal tissues. In addition, a third form of mucosal immune defense is contributed by regulatory cells wbich act in both epithelium and submucosa as well as in extramucosai tissues mainly through tbe production of soluble mediators. Although these cells may regulate IgA anfibody formation and the development of cell-mediated cytotoxic responses, tbey participate in the maintainance of mucosal tolerance against most environmental matters and as such can be regarded as key players in mucosal defense against inflammation.

Immune responses expressed in mucosal tissues are typified by secretory immunoglobulin A (S-IgA) antibodies. S-IgA constitutes the predominant Ig class in human externa! secretions, and is the best known entity providing specific immune protection for mucosa! tissues. Whi!e tbe syntliesis and assemUy of J chain-containing po!ymeric IgA mo!ecu!es is contributed to by p!asma ce!ls, mucosal epitbe!ia! ce!!s synthesize a secretory component whic!i acts as a ce!! surface receptor to faci!itate the transport of new!y formed IgA across epithe!ia! ce!!s. Tbe resistance of S-IgA against endogenous proteases makes antibodies of that isotype uniquely we!! suited to protect mucosal surfaces.

S-IgA antibodies provide "immune exclusion" of bacterial and viral pathogens, bacteria! toxins and otber potentially harmfu! mo!ecu!es, a function that appears to be facihtated by its affinity for binding to mucus. S-IgA has a!so been reported to neutra!ize directly a number of viruses (1, 2) , to mediate antibodydependent cell-mediated cytotoxicity, and to interfere with the utilization of grow-th factors for bacterial pathogens in the mucosal environment.

Mucosally derived S-IgA differs from bone marrowderived serum IgA, not only in terms of specific antibody activity but also in the proportions of polymeric vs tnonomeric forms (3) . The ontogenies of the mucosal and systemic IgA compartments display characterisfic and apparently independent patterns of maturation. Adult levels of S-IgA are reached in external secretions considerably earlier (1 month to 2 years) than in the serum (adolescence) (4, 5) . Experiments tbat addressed tbe origin of mucosal antibodies have indicated that an overwhelming proportion of such antibodies are produced locally in mucosal tissues and that only a minor fraction derive from tbe circulation in most species, including humans (6, 7),

Although tbe focus of most investigations has been on mucosal cytotoxic T lymphocytes (CTLs) induced by viruses, it should be borne in mind that antibody-mediated cytotoxicity and natural killer (NK)-cell activity are major responses associated with mucosal lymphocytes (8) (9) (10) (11) (12) (13) (14) . The re!evance of the latter responses in the field of mucosal vaccine development has not been ascertained and is therefore beyond the scope of this review.

Two major effector mechanisms associated with CTLs have been described: exocytosis from CTLs onto target cells of granules containing the pore-forming protein perforin and several serine proteases also termed granzymes, and ligation of a tumor necrosis factor (TNF) receptor-like molecule (Fas or CD95) on the target cell by FasL or TNF on the CTL side (15).

An early sudy demonstrated that intraperitoneal immunization with an allogenic tumour induced specific CTLs in the gut lamina propria and epithelium at a time when very few cytotoxic lymphocytes could be detected in peripberal lymphoid organs (9) .

It is now estabhshed that administration of certain enteric (38, 39) .

CTLs in ihe gcniiol tract mucoso The rhesus macaque model of vagina! infection with simian immunodeficiency virus (SIV) has been usefu! in studies of local immunity to SIV in the female reproductive aact (40) .

Recent studies in this mode! have provided direct evidence that pCTLs occur in female macaque reproductive tis.sues, and that infection with SIV induces effector CTL responses in the vaginal mucosa (41) , Interestingly, macaques vaginally infected with an SIY/HIV-l cliimeric virus (SHIV) displayed gag-specific CTLs in peripheral blood and resisted two challenges with virulent SIV (42) .

In a recent study involving HIV-1 infected women, cervical T-cell lines established from cytobrush specimens were shown to lyse autologous targets expressing HIV-1 proteins (43) . Class As CD4+ Th cells differentiate in response to foreign antigens, they produce distinct cytokine arrays. Naive (pTh) cells first produce interleukin (IL)-2) and then develop into T cells producing multiple cytokines (including both IFN-7and IL-4), a stage often termed ThO (45, 46) . The tissue microenvironment (47) , the cytokine milieu and the nature of the antigen influence the further differentiation of ThO ce!!s. Thus, infection with intracellular bacteria !eads to t!ie formation of Th 1 ce!!s and these ce!!s often deve!op fo!!owing production of IL-12 by activated macrophages (48, 49) , Exogenous antigens in the mucosa! microenvironment can trigger CD4+, NK1,1 + T cells to produce IL-4 for initiation of Th2-type responses (from ThO cells) (50, 51) . Th2-type cells also produce IL-4 for expansion of the Th2 subset as well as IL-5, IL-6, IL-9, IL-10, and IL-1 3 (5 2-5 6). This Th2 array may include production of IL-4; however, the reader should appreciate that individual cytokines are regulated through different signal transduction pathways so tbat all Thl or Th2 cells do not produce the entire array. The Th2 array of cytokines is of importance for B-cell isotype switches, and for supporting IgGl, IgG2b, IgE, and IgA responses in the mouse system (54, 57, 58) .

Thl and Th2 cells are also sensitive to cross-regulation by each other. For example, IL-12 and IFN-y produced by Th 1 cells inhibits proliferation of Tb2 cells, causes an isotype switch from IgM to IgG2a (50) , and inhibits isotype switching induced by IL-4 (59) . Conversely, Th2 cells regulate the effects of Thl cells by secreting IL-10 which in turn inhibits Thl cells, from secreting cytokines such as IL-12 and IFN-7, thus decreasing IFN-y-mediated inhibition of Th2 cells.

While the bulk of availab!e evidence in mice suggests that mucosa! tissues favor tbe development of Th2-type responses, the situation is not as clear-cut in humans. Thus, freshly isolated human lamina propria T cel!s contain an exceptiona!!y high frequency of IFN-y-producing ce!!s (60, 61) but comparatively few ceUs producing IL-4, IL-5 or IL-10 (61). Furthermore, even in mice, infection with recombinant Salmondla !eads to the formation of Thl ceUs and Th2 ce!!s in Peyer's patches (62) . On the other !iand, induction of IgA production to protein antigens is highly dependent on T helper cells (63) (64) (65) (66) (67) (68) (69) (70) (71) . In humans, TGF-p and IL-10 in concert with IL-4 have been shown to promote B-ce!! differentiation into IgA-producing ce!!s (64, 65) , In this regard, it appears that in addition to resident T ceUs, which produce !arge amounts of IL-4, IL-10 and transforming growth factor (TGF)-p, human epithelia! ce!!s, a!so of intestina! origin, provide a major source of TGF-p and IL-10 (unpublished observations). T!iis suggests that co-operation between neig!iboring lymphocytes and epit!ie!ial ce!!s in the mucosa! microenvironment is pivota! not on!y to promote the se!ective transport of new!y formed IgA across epithe!ia but a!so for programing preferentia! maturation of IgA-committed B ce!!s.

Finally, an additional type of CD4"^ regulatory T cell has been cloned from tbe mesenteric lymph nodes of rodents fed repeatedly wit!i antigens (72) . T!iese ce!!s or "Tb3" cells, produce TGF-p, variable amounts of IL-4 and IL-10, but no IL-2 or IFN-7, and appear to exert downregu!atory properties on Thl ce!!s (73) . Since TGF-p happens to serve as switch factor for murine and human IgA, and appears to p!ay a major ro!e in mucosa! to!erance (reviewed in (74) ), these ce!!s may have an important function in mucosa! homeostasis.

Mucosal inductive sites and generation of disseminated and compartmentalized secretory immune responses Generation of an immune response at mucosa! surfaces, where many significant infections begin, is not readily aclheved by the corfventiona! route of parentera! injection, a!thougb t!iis is usua!ly effective in e!iciting circu!ating antibodies and systemic cell-mediated immune responses. In contrast, mucosa! administration of antigens may resu!t in the concomitant expression of antibody responses in various mucosa! tissues and secretions, usna!ly without a pronounced systemic immune response (85).

Extensive studies concerning the origin of B-and T-!meage !ymphocytes that u!timate!y popu!ate mucosa! tissues and secretory g!ands, and of immunization routes effective in the induction of secretory antibody responses, indicated that the MALT can be divided into two functiona!!y distinct compartments; namely, inductive and effector sites. This physiological division is of paramount importance in the design of vaccines effective in the induction of protective immunity within the mucosal immune system and, in particular, its humoral branch.

Experiments performed in animal models and more recently in SCID mice engrafted with human mucosal lymphoid cells revealed that the inductive sites present in certain locations, such as Peyer's patches in the smal! intestine, or in some species the tonsi!s in the upper aerodigestive tract, function as primary sources of precursor ce!!s that migrate through the !ymp!iatics and b!ood, and after directed extravasation populate remote mucosal tissues and glands (75) (76) (77) (78) . These studies have !ed to the notion of a common mucosa! immune system (Fig. I) .

It is genera!!y be!ieved that antigens taken up by specia!ized epit!ie!ia! ce!!s ("M" cells or "membranous cells") covering mucosal inductive sites can be channeled to parenchymal macrophages, DCs, B lymphocytes, and even mast cells, and/or they can be processed and perhaps presented directly by epithelial cells to underlying B and T ce!!s. Fo!!owing interaction of the antigen with accessory ce!!s and cognate helper T ce!!s and/or B lympiiocytes in the Iocai iymphoid microenvironment, an immune response may ensue. With the majority of antigens tiiis results presumahly in suppression of specific immunity -"mucosai toierance" (see beiow), However, deveiopment of an active immune response may also foiiow mucosal intake of atitigen, and the characteristics of the immune response generated, inciuding tiie baiance hetween active immunity and suppression/toierance may be influenced by several factors, inciuding the nature ofthe antigen, the type of accessory ceiis, cytokines and iymphocytes invoived, atid the genetic background of the host. Two major types of active immune responses may deveiop either concomitantiy or separateiy: antibody formation (mainiy SIgA) and ceii-niediated immunity. The sensitized immunocytes, in particuiar antigensensitized B cells but presumahly aiso T ceiis, leave the site of initial encounter with antigen, e.g. a Peyer's patch, transit through the thoracic duct, enter the circuiation and then seed both that same mucosa and other distant yet priviieged mucosai sites. In tiieir new iocations, tiie committed B ceiis may further differentiate into piasma ceiis producing antihodies, mainiy dimeric IgA, under the infiuence of iocally produced cytokines.

This IgA celi cycie was first eiucidated in animais tiirough the adoptive transfer of ceiis from the gut-and hronchus-associated iymphoid tissues (GALT and BALT) into recipients whose mucosai tissues and giands were popuiated hy IgA piasma ceiis of donor origin. Most importantiy for vaccine deveiopment, evidence for the existence ofa common mucosai imtnune system in humans has been strengthened in recent years by severai studies. In addition to the detection of specific S-IgA antibodies in remote secretions induced by natural exposure to antigens or orai immunization, anaiyses of IgA-secrecing ceiis from peripheral biood and mucosai tissues after enteric immunization provided strong support for this concept system, this finding may explain both the unification of humoral immune responses in diverse mucosal sites and the physiologic segregation of mucosal from non-mucosal immune mechanisms. Based on the concept of a common mucosal immune system through which a fraction of lymphocytes activated in the gut. e.g. hy iugestion of antigen, can disseminate immunity not only in the intestine hut also to other mucosal and glandular tissues, there is currently inuch interest in the possibility of developing oral vaccines against both enteric and non-enteric tnucosal infections, e.g. in the respiratory or genital tract. However, recent studies involving immunizations of human and non-human primates as well as rodents with prototype nonreplicating immunogens, such as cholera toxoids or cholera toxin indicate that a substantial degree of subcompartmentalization exists within the mucosal immune system, and even within a given mucosal organ such as the gut, regarding both homing of IgA plasma cell precursors and final redistrihution of their progenitors.

The MALT is comprised of anatomically defined lymphoid microcompartments, such as the Peyer's patches in the small intestine, the appendix and solitary follicles in the large intestine and in the rectum, the nasal mucosa and the tonsils at the entrance ofthe aerodigestive tract, which serve as the principal mucosal inductive sites where immune responses are heing initiated (84-87). It also contains diffuse accumulations of large numbers of lymphoid cells that do not associate into apparently organized structures. These cells are either distributed in the lamina propria or interspersed among epithelial cells in mucosal tissues and glands, and form the mucosal effector sites where immune responses are being expressed. The gut mucosa is particularly well invested with such diffuse lymphoid tissues.

More important for vaccine development is the fact that immunization at certain inductive sites may give rise to a humoral immune response preferentially manifested at certain effector sites. Thus, a given inductive site may serve as a preferential but not exclusive source of precursor cells for certain mucosal tissues. lmmunoio}]kfll Reviews 17071999 Inductive sites in the gut-associated lymphoid tissues (GALT) The gut contains tbe most abundant !ymphoid tissues and inc!udes organized as we!! as diffuse lymphoid e!ements. Organized !ymphoid tissues are comprised of two units -B-ce!! follic!es and para-or interfo!hcu!ar T-ce!! areas -assemb!ed within a matrix of !oose connective tissue and fo!licular DCs. These foUic!es occur sing!y or in groups and harbour variab!e numbers of macrophages and T ce!!s (88).

Fo!!ic!e-dome structures form the main !ymphoid component of the Peyer's patches in the jejunum and i!eum and are a!so found in the !arge intestine, and especia!!y in the appendix. These structures appear to p!ay an important ro!e in the induction of disseminated immune responses to ora! vaccines (Fig. 2) , Typica!!y, the fo!!ic!es contain a majority of B ce!!s, approximate!y half of which are activated. The T-cel! zone comprises a majority of CD4+ T ce!!s; CD8+ ap TCR T cells are main!y located in the parafo!licular area whereas CD8+ yS TCR T cells are rare. The dome is covered by a specia!ized epit!ie-!ium or "fo!!ic!e-associated epiche!ium" (FAE), containing antigen-transporting M ce!!s.

The ceca! and co!onic mucosae are a!so variably invested with comparab!e !ymp!ioid patches, although the epithehum covering t!iese !ymphoid aggregates does not show the specia!izations of M-ce!!-containing FAEs (89, 90).

C!usters of fo!lic!es are a!so found adjacent to the ano-recta! junction (91, 92). T!ie potentia! importance of the recta! !ymphoid tissues as an IgA inductive site and as a source of IgA plasma ce!! precursors is suggested by several studies. First, the predominance of IgA2 ceUs over IgAl cells in the lamina propria of the !arge intestine c!ear!y diverges from the re!ative apportioning of the two in other mucosa! tissues, such as in the smal! intestine and in the upper !arge intestine (93). Fnrt!ier, recta! immunization of humans, non-human primates and rodents has been shown to induce strong secretory antibody responses in the recta! miicosa. Although in most instances, rectal immunization induced secretory antibody responses in therectal mucosa itself (94-100), in some instances, rectal vaccination con!d induce specific antibodies in serum, and a!so in secretions from remote mucosa! organs, such as sa!iva (102), and genita! secretions (92-94, 96). A!though the potentia! of the recta! mucosa to serve as site of induction of mucosal responses is now wel! estab!ished, it shou!d be pointed out tbat rectal immunization of macaques wit!i CT, one of t!ie most powerfu! mucosa! immunogens, was shown to be poor!y effective at inducing an immune response in the upper part of the intestine and especia!!y in the smai! intestine (100).

Recently, a new type of "organized" lymphoid tissue, termed the cryptopatch, has been identified in the murine intestine (101). These consist of microscopic aggregates (a fewhundred ceUs) of immature !ymphocytes c!ustered in die !amina propria. Although cryptopatches have not yet been identified in humans, it has been proposed that they represent a precursor source of intestinal intraepithehal T ce!!s. The potentia! ro!e of these structures in the induction of active immunity or to!erance to mucosaUy encountered antigens remains to be exp!ored.

Inductive sites in the naso-pharyngeal lymphoreticular tissues (NALT) Severa! recent studies have emp!iasized the importance of the nasa! cavity for the generation of mucosal and systemic immune responses that may exceed in magnitude those induced by ora! immunization (83, 102-111), When introduced into the nasa! cavity, usua!!y a!ong with mucosa! adjuvants, vira! and bacteria! antigens induce superior immune responses in externa! secretions such as sa!iva and, surprising!y, ill fema!e genital tract secretions. Because neither IgG nor IgA antibody titers in vagina! washes corre!ate with serum antibody responses, it is assumed that antibodies of both isotypes are predominantly of mucosa! origin. This finding may have important imp!ications for the design of vaccines effective in the induction of immune responses in the genital tract.

Tbus, different immunization routes (intranasal and oral) can induce genera!ized mucosa! immune responses, although the relative representation of dominant antibody isotypes may vary. Neverthe!ess, nasa! immunization appears to induce S-IgA immunity in a broader range of mucosa! tissues t!ian ora! vaccination. This may be exp!ained by the recent observation that circulating IgA-secreting ce!!s induced after nasal vaccination express a more promiscuous profi!e of homing receptors than t!ieir corresponding counterparts raised after ora! or recta! immunization (82, 83), Whether such antibody responses are a!so induced in the ma!e genita! tract remains to be determined.

Immunohistochemica! studies have indicated that the epithe!ium of the human nasa! mucosa contains intraepithe!ia! !ymphocytes (IFLs) staining predominantly for CD3, CD2, CD8, and CD5, but !acking Leu8 (homing receptor analogue of Me!l4) (123, 124). Pew (<10%) nasal IELs stain for CD4. Nasal IFLs rare!y express HMLl, whereas t!ie majority of intestina!, tonsi!!ar and adenoidal IELs are HMLl'. HLA-DR+ intraepithelial DCs cells have a!so been identified in nasa! mucosa specimens, VirtuaUy no B ce!!s and no organized subepithelia! lympboid tissue are found in the norma! human nasa! mucosa. In contrast, the nasa! mucosa of adu!t rats and mice comprise !ymp!ioid structures witb distinct T-and B-ce!! areas (112, 113). Furtbermore, the majority of intraepitheha! !ym-phocytes populating the nasal epithelium are slg+ B cells with a few CD4+ or CDB"^ T cells in rats (112), whereas the murine nasal epithelium is infiltrated mainly with CD4"^ T lymphocytes with very few B cells (113). Thus, the human nasal mucosa seems to differ from that of rodents -the most commonly used animals in preclinical vaccine studies -and also from endcjdermaily derived hunian mucosae, such as the tonsils and adenoids. The latter lymphoid structures appear to be the major Thus, within the context ofthe common mucosal immune system, certain organs may favor the development of IgA-committed precursors B cells whose progeny is preferentially destined to particular mucosal locations. This new knowledge should call for more site-directed vaccination strategies,

Since Jenner introduced vaccination over 200 years ago, fewer than 50 vaccines have been approved for human use, nearly half of which are improved versions of earher forms. All but five of the current vaccines -the oral poliovaccine, the oral killed whole cell7B subunit cholera vaccine, the oral Salmondia typhi vaccine, an oral rotavirus vaccine and nasal live-attenuated influenza virus vaccines which have completed phase III clinical testing -are administered parenterally and as such do not provide significant mucosal immunity.

It is now almost axiomatic that in order to be efficaciotis, vaccines against mucosai Infections must stimuiate the MALT, atid that this goai is usually better achieved by administering immunogens by a mucosal route rather than parenteraiiy. However, even so, stimulation of secretory immune responses by mucosai administration of most non-repiicating antigens is often reiativeiy inefficient, requiring niuitipie administrations of iarge quantities of immunogens and yieiding most often toierance and, if at ali, modest immune responses. Tiiis conclusion is pliysiologically justifiabie since the primary function of tile mucosai immune system is to prevent the overstimuiatioti ofthe entire immune system. It does so by eliminating mucosaiiy appiied antigens witii denaturing acids, degradative enzymes and otiier innate factors as weii as through intestinai peristalsis and ciliary movement on epithelia in the respiratory tract.

Against tiiis baciiground, mucosai vaccinoiogists have eiaborated numerous deiivery systems and adjuvants which partly circumvent such naturai obstacies. The ever-growing list of mucosai deiivery systems described in tlie iiterature bears witness to the difficuities encountered and to the hmited practical usefuiness of most deiivery devices. We wiii therefore concentrate on the most promising systems. Furthermore, it shouid he emphasized that most of the resuits have heen obtained in animai modeis rather than in humans with ali unavoidahie iimitations.

Inert vaccine delivery systems Because antigens are more immunogenic in particuiate form than in soiutions, and hecause they are vuinerabie to antigendegrading enzymes and acids, tiiey have often heen incorporated into vehicles that are by themseives non-toxic and nonimmunogenic, and whicii protect vaccine materiai from degradation, enhance tiieir uptake fr(Dm mucosai surfaces, and may exhihit an adjuvant effect, Geiatin capsuies coated with suhstances (e,g, ceiiuiose acetate phthaiate) that dissoive at alkaiine pH in the intestine but not at acid pH in the stomach have been used for orai dehvery of bacteriai and virai vaccines in severai studies performed in humans but tiieir usefulness has never been systematicaliy assessed (125-127),

To avoid the fast passage of free antigens, mucoadhesive polymers that adhere to mucosal surfaces and thus extend the time of exposure of vaccines have been used in severai recent studies (123, 128, 129) . When compounds suchashighiy viscous inert poiysaccharide eldexomer (123) and carboxymethyl ceiiuiose (128) are used with an antigen such as infiuenza virus or CT-B that has been orally, intranasaliy, or intravaginaiiy administered, botii Iocai mucosal and systemic immune responses are induced. Other compounds that have heen considered are carhapol, poiycarbopiii, sodium algiiiate, and hydroxypropyl cellulose, which are used in medicine for drug delivery

Liposomes have been used for mucosal vaccination in a few studies, while bacterial or viral antigens iiave been administered oraiiy or intranasaiiy to rodents, moniseys and humans, resulting in the induction of mucosai and systemic immune responses (reviewed in (130)), A related antigen delivery system, cochieates, composed of protein-phosphoiipid-caicium precipitates with entrapped antigens, has heen used for mucosai deiivery of giycoproteins or peptides from influenza virus and SIV (131), As with iiposomes, humoral as weii as ceii-mediated immunity (CMI) have been induced wiien given by tiie oral route, Biodegradabie microspiieres composed of antigens incorporated into poiymers of iactic and giycoiic acid iiave been used far more extensively in mucosai vaccinoiogy than any other inert deiivery system (132) (133) (134) (135) . Microspheres have gained popularity hecause of their stability whicli allows them to protect incorporated antigens from acids and enzymes, and because of the ease with wiiich their size and rate of biodegradation can be modified. Further, microspheres are by themseives non-antigenic and so can be easiiy reused, offering an advantage over live vectors. The rate of release of antigens can theoretically be controiied by mixing fast-and siow-releasing microspheres, aliowing for the induction of combined primary and secondary immune responses by a singie immunization (132), Finaiiy, it wouid seem possibie to incorporate immunoreguiatory cytoicines or DNA encoding for different antigens to aciiieve a desired immune resp(3nse, and attempts to do so are in progress.

These obvious attractive features of tlie inert delivery systems are counterbaianced by serious disadvantages, Specificaiiy, the disappointingly low absorption rate, usuaiiy much iess tiian 1% of the ingested dose, renders the procedure expensive. Moreover, the use of organic solvents during the incorporation of antigens may severeiy compromise the immunogenicity of sucii vaccines. However, attempts are heing made to increase the ahsorption rate and to deveiop conditions of incorporation that minimize degradation of antigens.

Mucosal iectin-like molecules as carrier-delivery systems Oral administration of small amounts of protein antigens covalently coupled to carrier moiecuies with known affinity for mucosal epithelial cells, such as CT, Escherichia coii heat-labile toxin (LT), CT-B and LT-B, can eUcit mucosal and also, under certain conditions, systemic antibody responses to the conju-gated antigen (136) (137) (138) . This strategy has also recently been utilized to induce mucosa! immune responses to carbohydrate antigens (139), Fusion proteins created from hybrids of CT-B or LT-B with genes encoding !ietero!ogous antigens have a!so been generated (140, 141) , and are preferable to chemicaUy coupled proteins in that they are free of contaminating ho!otoxin and are uniform in structure. Overexpression systems have a!so been developed to facilitate !arge-scale prodttction of such fusion proteins (142) . Others have created fusions between antigens and CT-B-CT-A2 mutants which lac!i the toxic Al subtmit (143) (144) (145) . Interestingly, though oral administration induced serum IgG antihodies, maximttm niuccjsal IgA responses required addition of t!ie who!e CT. Thus, it appears that CT-B is an exce!!ent carrier mo!ecu!e due to its ability to bind to GMl receptors on epithelial cells but at best exhibit low adjuvant properties.

Live recombinant microorganisms as mucosal delivery s/tems It has long been assumed that on!y !ive vaccines wotdd efficient!y stimu!ate a tnucosa! immune response since the majority of microbial pathogens co!onize or enter t!irough mucosa! surfaces and hence have evolved strategies to circumvent natura! physico-chemica! barriers. Furt!iermore natura! infection The ability of a vector to co!onize specific mucosa! !oca!es and so to generate an immune response at desired sites is an important factor in determining its suitabihty as vaccine vebic!e. The most important factor to be considered is the abi!ity of a given Intranasa! immunization has emerged as perhaps the most effective route for induction of both periphera! and mucosa! immimity to vaccines. The usefu!ness of Mycobacterium bovis strain Baci!!e Ca!mette Guerin (BCG) as a delivery system for recombinant antigens has been documented in severa! mode!s. Specirica!!y, BCG-vectored outer surface protein and pneumococca! protein A conferred protection against Borrelia and S, pnetimoniae, respectively, when given nasa!!y to mice (reviewed in (156)).

Recently, attenuated Bordetella pertasis strains have been constructed by deleting the pertussis toxin gene and have been used as !ive vectors for intranasa! de!ivery of hetero!ogous antigens expressed at tlie surface of B. perttis.d:i via fusion to the fi!amentous heinagg!utinin (VRA) gene (157) . Intranasal delivery Immunological Rmeivs 170/1999 of B, pertussis expressing a parasite antigen fused to FHA induced strong mucosa! immune response but re!ative!y modest serum antibody responses to the fused antigen. Nevert!ie!ess, such an approach cou!d be used for the construction of combined vaccines to protect not on!y against whooping cough but a!so against otlier respiratory infections.

Adenoviruses (r-Ad) have proven to be rather attractive systems for tissue targeted de!ivery of mamma!ian and microbia! genes in gene therapy and in vaccino!ogy, respectively. MVA holds promises as a safe and effective mucosa! vaccine de!ivery system. More genera!!y, suc!i non-rep!icative poxvira! vectors are promising mucosa! delivery systems.

The use of RNA viruses as vectors initia!!y !agged behind the use of DNA viruses, main!y due to the re!ative ease of manipu!ating DNA genomes. Given the progress in recombinant DNA techno!ogy, the deve!opment of RNA viruses as vac-208 Immunoiogical Rei'ims 170/1999 cine vectors has now caught up with DNA viruses (reviewed in (178) ). Recombinant vaccine strategies using RNA viruses such as poliovirus, alphaviruses (Venezuelan equine encephalitis virus (VEE), Semliki Forest virus), aud paramyxoviruses (RSV) as vectors are being actively explored for mucosal immunization. In particular, replication-competent VEE expressing HIV pl8 and p24 gag (179) or influenza virus HA genes (1 80) have been shown to induce mucosal and cellular immune responses. Interestingly, a replicon vaccine vector system was developed frcmi an attenuated strain of VEE (181), The replicon RNA consists of the cis-acting 5' and 3' ends of the VEE genome, the complete non-structural protein gene region, and the subgenomic 26S promoter. Immunization of mice with the VEE replicon expressing the influenza HA or Lassa virus N gene induced ancibody responses against the expressed protein and demonstrated a capability for sequential immunization to multiple pathogens in the same host (181), Likewise, recombiuant poiiovirus can be engineered as replication-competent vector (182) or as replicon (183) (reviewed in (178)). The unique aspects of these viruses, including their port of entry, point to promising developments in mucosal vaccinoiogy,

Since Wolff and colleagues (184) reported that direct intramuscular injection of mice with plasmid DNA encoding the complete sequence of a gene resulted in durable expression of the encoded protein, immunization with plasmid DNA encoding virulence genes of several important pathogens has been shown to Induce protective immunity in several preclinical studies (185) . Although many issues, including safety considerations, will need to be carefully assessed, this approach offers substantial advantages. Aside from stability and ease of production, these include the induction of immunity by a non-infeciious agent, aud thus the possibility of vaccinating against organisms wilh a propensity for long-term persistence in the body e.g. cytomegalovirus and HIV Furthermore, DNA immunization would allow the selection of nucleic acids corresponding to a broad range of polypeptides to overcome the problem of MHC genetic restriction in outbred populations. In addition, the plasmid backbone can also be equipped to harbour sequences encoding cycokine genes so as to facihtate the type of immune response desired.

In principle, the DNA used for vaccination is a plasmid couiaining a bacterial origin of replication aud an antibiotic resistance gene, required for selective plasmid production in E, coli. The gene of interest is cloned under the contro! of a strong promoter (usually a viral promoter), Iu addition to the expression cassette, the plasmid may contain immunostimulatory sequences which appear to be critical in governing the immunogenicity of the expressed gene. These sequences include a non-methylated CpG motif within a palindromic hexamer oligonucleotide sequence (186, 187) and have been reported to induce B-celi proliferation (188) and Thl cyCokine production (189, 190) , The stimulatory properties of such motifs appears to be mediated via the selective activation of DCs (191) . It is interesting to note that mucosal administration of synthetic oligodeoxynucleocides containing CpG motifs enhances virus specific responses, suggesting that such nucleotides could be used also as mucosal adjuvant (192) .

Although the majority of studies so far have dealt with inCracutaneous and intramuscular administration of DNA vaccines, this approach has gained popularity among mucosal vaccinoiogists. Naked plasmid DNA can be directly used for mucosal immunization (193) (194) (195) (196) (197) , Thus, intranasal or iutratracheal administration ofa DNA plasmid enccjding influenza virus hemaggiutinin induced protection against a lethal influenza virus challenge in mice (185) . More recently, intranasal immunizacion of mice with a DNA plasmid encoding iacZ and herpes simplex virus type 1 glycoprotein B (gB) induced lacZ and gB expression in lungs and cervical lymph nodes (195) . Although a distal mucosal IgA response and an anti-HSV cell-mediated immune response were observed following three i,n. administrations of gB DNA, protection against lethal vaginal HSV challenge was lower than that seen after intramuscular administration of the same plasmid. Intrabuccal injection or nasal administration of plasmid DNA encoding measles virus hemaggiutinin induced systemic MHC class I-restricted CTL responses (196) . Further, intravaginal instillation ofa plasmid DNA encoding the HIV-1 envelope glycoprotein elicits production of IgA and IgG antibodies in vaginal fluids and serum neutralizing antibodies (194) . The same construct was employed to demonstrate that plasmid DNA vaccination of infant chimpanzees was well tolerated and could induce serum antibodies to HIV-1 (197), As for conventional vaccines, several formulations have been developed to faciiitate the uptake of plasmid DNA-based vacciues and to protect chem from degradation in the mucosal microenvironment. The use of liposomes, cationic lipids, monophosphoryl lipid A for mucosa! delivery of DNA (198) (199) (200) (201) has been shown to increase both expression and immunogeuicity ofthe corresponding protein, suggesting thac the lipid matrix may also provide a secondary role as adjuvanc by facilitating DNA uptake by APCs or by promoting local inflammation. Iu che case of oral delivery, plasmid DNA can also be protected from degradation in che guc by encapsulacion Immunological Reviews 170/1999 in poiy(DL-iactide-co-glycohde) (PGL) microparticles (202, 203) , Attenuated intraceliular bacteria sucb as Salmoneiia, wbicb are retained within vacuoies in tbe infected ceii. iiave recentiy shown promise for tile dehvery of plasmid DNA. Thus, infection of peritoneal macrophages with S. lyphi carrying a plasmid encoding lac Z resuits in the transfer of piasmid DNA into tbe infected ceii (204) . Very recentiy, this approach has been employed to demonstrate tbat orai administration of S. typhi carrying a tumor antigen resuits in gene transfer in host DCs and protects mice against fibrosarcoma (205) .

The mechanisms underlying tbe induction of an immune response after mucosal DNA vaccination are stiii unknown, but are hkely to be analogous to those involved after systemic (intramuscular, intradermai) DNA administration (206) (207) (208) (209) : transfer of antigen from tissue-transfected epitheiiai cells to professionai mucosal APCs (cross-priming), or direct transfection of professional APCs and especiaiiy DCs.

Mucosai vaccines wouid be more wideiy used -especiaiiy in developing countries -if they couid be produced at lower cost, and distributed without refrigeration. The concept of vaccine production in transgenic plants was introduced recentiy (210), and was based on the premise that plants have the capacity to produce abundant biomass, and that recombinant immunogens could be produced in plant tissues. Since plants can be engineered to contain muhiple foreign genes, multicomponent transgenic plant vaccines should therefore be feasible. Severai piant expression systems, e.g. potato and tobacco plants, have been developed and sbown to aiiow expression of microbiai antigens such as hepatitis B surface antigen, E. coli LT-B, and even Norwalk Virus-like particles (VLPs) (reviewed in (211)). Although the ieveis of expression of recombinanl antigens bave so far been very disappointing, feeding animais with potato tubers expressing Norwalk VLPs or E. coli LT-B induced specific secretory IgA antibody responses and serum IgG responses to the transgenic protein (211) . Developing strategies lo increase antigen expression in edibie plants, inciuding tbe use of strong tissue-specific promoters remain one important ciiallenge in tiiis area of vaccine deveiopment.

DCs are potent APGs that piay a centrai roie in the induction of immunity as initiators and immunomoduiators of immune responses (212). Owing to their capacity to prime T ceiis, DCs ioaded ex vivo with tumor antigens have been extensiveiy used as potentiai cancer vaccines (213, 214) . Given promising pre-ciinical resuits, studies are now underway in patients. That adoptive transfer of DCs pulsed ex vivo with infectious microorganisms could constitute a way to induce broad-based immunity against infectious diseases lias also been documented (215) (216) (217) ,

To date, the potential of DCs as vaccine carriers for the induction of mucosal responses is largeiy unknown. In this respect, a recent study has shown that DCs puised ex vivo with kiiled ciiiamydiae and subsequently transferred into naive recipients were abie to induce protective CD4"^ Thl immune responses against genitai chaiienge with cblamydia (218) . Altbough this study used bone marrow-derived DCs, it is the first one to document tbe efficacy of this approach against a mucosai infection.

The introduction of proteins inciuding vaccines into mucosal inductive sites is an effective way to induce systemic unresponsiveness (mucosai tolerance). Thus, mucosal adjuvants are required not only to boost mucosai and systemic immunity, but aiso to prevent the induction of mucosai tolerance.

Although a variety of compounds have been reported to display adjuvant properties on mucosaliy co-administered antigens, the most powerful and hence most studied mucosai adjuvants are tlie Vibrio ciiolerae exotoxin CT, and its structurai and bioiogicai anaiog LT, Tbese macromolecuies are composed of tw-o structuraiiy, functionaiiy and immunologicaliy separate A and B subunits (219) . The B subunit of botii toxins consists of five identicai monomers, but the pentameric B subunit of GT (CT-B) binds oniy to GMl ganglioside, while tbe B subunit pentamer of LT (LT-B) is more promiscuous and binds to GMl as weil as to asiaio GMl, GM2, and giycoprotein receptors (220) . After the B subunit binds to epitbeiial ceil GMl or GM2 receptors, the A subunit reaches the cytosoi and binds to NAD to cataiyze ADP-ribosyiation of Gsa. This GTP-binding protein activates adenyi cyciase witii subsequent eievation of cAMP. whicb in epithelial celis results in secretion of water and chloride ions into the small intestine.

Mucosal exposure to CT and LT, whicii are botii immunogenic, resuits in S-IgA and serum IgG antibodies, wiiich are aimost entirely restricted to CT-B or LT-B. More importantiy. botb toxins are potent mucosal adjuvants for unrelated proteins co-adniinistered by orai, intranasal or even parenterai routes (221) (222) (223) .

Recent studies suggest that orai or nasal immunization with proteins aiong with GT as adjuvant induces Th2-type responses in the intestinal mucosa (224) (225) (226) . Such an immu-nization protocol induced CD4+ Th2 cells in Peyer's patches and the spleen (224) as well as higb IgGl and IgE responses, in the absence of detectable IgG2a titers (226, 227) . Further, oral immunization with keyhole iimpet hemocyanin (KLH) and CT mixed with CT-B resulted in Peyer's patch and iamina propria T-iymphocyte popuiations whicii produced iow IL-2 and IFNybut higii ieveis of IL-4 and IL-5 (228), However, otber studies have showii tbat oral co-administration of a soiubie or particuiate antigen and CT primed animals for systemic Thl-type immune responses (delayed-type bypersensitivity) (229) and induced functional GTLs in the spieen (230) . Again, the resuits from these studies suggest that orai immunization with heteroiogous antigen and CT as an adjuvant can differentiaiiy affect mucosal and systemic immune responses, inducing Tb2-type immtme responses in mucosal tissues aud Th2 as well as Thl-lype responses in the systemic compartment. Tbus, not only the nature of the adjuvant, but also tiiat of tbe antigen used, and the mucosal route of delivery can ail influence wbether Tbl-and/or Th2-type responses develop.

CT and LT cause severe diarrhea in iiumans and account for tiie clinical manifestations of choiera and enterotoxigenic E. coli enteritis, and tbus neither is suitable for use as an enteric adjuvant in humans. Early studies attempted but faiied to dissociate diarrhoeagenicity from tbe adjuvaniicity of these two moiecuies. For exampie, a non-toxic mutant, formed by making a singie amino acid substitution in tbe ADP ribosyitransferase active center also lacked adjuvanticity when administered oraliy (231) , However, mutants of LT formed by substituting a single amino acid eitiier in or outside the ADP-ribosyitransferase cieft, retained adjuvanticity despite apparent iack of toxicity wben administered by the intranasai route (108, 232-234). Moreover, two mutants of GT, which harbor single amino acid substitutions in the ADP-ribosyltranferase active center and completely iack ADP-ribosyitransferase activity and diarrheageniciiy, remained effective adjuvants and were comparabie to native CT wben given parenteraiiy or nasaiiy (235, 236) , We have ourselves found that recombinant CT-B and LT-B are aiso moderateiy adjuvant when co-administered with otber protein antigens by tile nasai route but not by tiie orai route (C, Czerkinsky. J. Hoimgren, unpublished observations). Since enterotoxicity is tbe main obstacle to the use of native CT or LT as oral adjuvants, it will be interesting to determine whether enzymatically inactive CT and LT mutants have retained adjuvant activity when given orally.

One of tiie primary goais in developing effective therapies against diseases caused by unwanted or tissue damaging inflammatory immune responses, is to specificaiiy suppress or decrease to an acceptabie level tbe intensity of untoward immune reactions witbout affecting the remainder of the immune system. Induction of tolerance in mature pathogenic T celis represents an ideai form of specific immunotberapy in the treatment of chronic inflammatory autoimmune disorders and allergies.

Three main modes of peripiierai toierance induction by antigens have been considered: parenterai administration of antigens, parenteral administration of antigen analogs whicii act as T-ceii receptor antagonists, and mucosai administration of antigens or so-cailed "orai toierance". Mucosal administration of antigen is in fact a iong-recognized method of inducing peripherai toierance. The piienomenon, often referred to as "oral tolerance" (because it was initially documented by the effect of oral administration of antigen), is characterized by the fact that animals fed or having inbaied an antigen become refractory or have diminished capabiiity to deveiop an immune response when re-exposed to the same antigen introduced by tbe systemic route, e.g, by injection. Tbis effect is especiaiiy pronounced for Thl ceii-mediated immune responses and is regarded as an important naturai physioiogicai mechanism whereby we avoid deveioping deiayed-type iiypersensitivity reactions to dietary and airborne antigens, and products from commensal microorganisms. Mucosaliy induced immunoiogicai tolerance can affect ail types of adaptive immune responses, depending on tbe animal species, the age, the form and dose of antigen, and the route of mucosai administration (enteric, buccal. nasal, rectai, genitai).

Mechanisms of tolerance after mucosal delivery of antigens Mucosai uptake of antigens may resuit in the deveiopment of immunity or tolerance, or even botii, the decision being taken in the epithelium or underiying iymphoid tissue and being mainly determined by tiie nature and physico-chemicai form of the antigen.

Depending upon tbe dose of antigen administered, deietion or anergy of antigen-specific T cells and/or expansion of cells producing immunosuppressive cytokines (IL-4, IL-10 and TGP-p) (reviewed in (73) ), may result in decreased T-cell responsiveness. It is interesting to note that tbe latter scenario involves cytokines tbat are also known to promote IgA isotype switcbing and IgA production, and is thus compatible with tlie observation tbat secretory IgA antibody responses and systemic T-ceii tolerance may develop concomitantly (237) . Because toierance can be transferred by both serum and cells from tolerized animais, it is possible tbat bumorai antibodies (IgA?), circulating undegraded antigens or toierogenic fragments and cytokines may act synergistically to confer T-celi unresponsiveness. Without exciudiiig the above possibiiities, another mechanism that may be considered could involve antigen-driven attraction of infiammatory T ceiis from the periphery into the mucosai microenvironment where they could be rendered anergic, functionaiiy skewed, deieted or even ignored. Tbis form of antigen-driven "anatomic deviation" wouid imply that inflammatory T celis activated in peripheral tissues exhibit a promiscuous migratory behaviour aiiowing their entry not only in systemic organs but aiso in mucosai tissues at tbe site of antigen uptake. Tbe latter scenario has not yet been addressed experimentaiiy but is compatible witb studies sbowing tiiat arthritogenic and diabetogenic T celis do express tiie cell surface mucosal integrin a4p7 whose hgand, the mucosal addressiii ceiiuiar adbesion moiecuie (MadCAM-l). is also expressed on inflamed pancreas and synovial tissues. In this respect, it is aiso interesting lo note that oral tolerization with a prototype soiubie protein antigen iias recentiy been shown to differentiaiiy affect the production by peripherai T cells of tiie li (C-C) chemokines MlP-la and MCP-1 (238), wbich are potent chemoattractants for T celis.

Irrespective of effector mechanism(s) invoived, a major question that arises is where and bow toierance is induced, be it suppression, anergy, deletion, ignorance and/or anatomicai deviation. To date, very httie is known regarding the mechanisms governing induction of mucosal tolerance, and especially the intraceliular pathways of entry of tolerogens, tbe nature of APC eiements invoived, tiieir tissue iocahzation, and tbe characteristics of signais transduced from such ceiis to responding T ceiis.

At variance with systemicaiiy administered antigens, antigens fiandled in mucosai tissues bave aiready been subject to a variety of innate factors sucb as, e,g,, proteases, acids, saits, mucins, that have aitered their form prior to uptake. As a resuit of tbis "extratissuiar conditioning" different epitopes may be exposed and their uptake and/or processing may involve many different ceii types.

The observation thac mucosally induced systemic toierance depends on an intact epitheiiai barrier (239, 240) suggests a centrai roie for the epitheiium, M ceiis have been shown to uptake a variety of particuiate antigens such as viruses and bacteria, and to aiiow direct entry of invasive microorganisms in mucosal inductive sites. Such a patbway is thought to result in the induction of secretory IgA immune responses. Aithough tiie abiiity of M ceiis to serve as APCs appears to be pooriy sup-ported, these ceiis could still theoretically be involved in an abortive form of antigen presentation ieading to toierance induction. The roie of absorptive epitbeiiai ceiis, such as intestinai enterocytes, in toierance induction has been underscored by severai studies (reviewed in (241, 242) ). Epitheiiai enterocytes express co-stimuiatory moiecuies such as non-ciassicai MHC ciass 1 (CD i d) moiecuies involved in antigen presentation to subpopulations of T celis and abnormai forms or ieveis of MHC ciass II molecules, ieading to seiective triggering of suppressive CD8+ T cells and/or abortive presentation to CD4' T celis. In addition, epitbeiiai enterocytes bave aiso been shown to produce cytokines, such as IL-10 and TGF-p, which are particuiariy efficient at suppressing the inductive phase of CD4+ T-ceil-mediated responses.

Aii known types of ciassicai APCs. inciuding DCs, macrophages and B cells, and even mast celis, have been sbown to populate mucosai tissues but, because of their beterogeneity and of tbe difficuity in isoiating pure subpopulations of APGs from mticosai tissues, their respective roie in inducing toierance has not yet been elucidated. Aithough activated B ceiis and tissue macrophages are powerful APCs for memory Tb ceiis, evidence suggests tbat antigen presentation by resting B ceiis results in T-celi tolerance (243, 244) . It shouid bowever be noted that B ceiis activated in vitro with bacteriai iipopoiysaccharide (LPS). a prominent component of the normal mucosal microflora, are capable of inducing toierance wiien injected into naive hosts (244) . Aithougb functional DCs have been identified in mucosal tissues sucb as tbe Peyer's patches, tbe mesenteric lymph, the intestinal iamina propria and the airw-ay mucosa (reviewed in (245)), tiieir roie in activating rather than suppressing naive T cells has received strongest support. Thus, DCs freshly isolated from the airway mucosa preferentially activate Tb2 ceiis but can also mature into APGs capabie of activating Till (246) . Thus, airway DG cells could play a pivotai role in the cross-regulation of Thl-and Tli2-driven responses. However, recent experiments with splenic dendritic ceils have siiown a differentiai capacity of these DC subpopuiations to activate T ceiis, suggesting the existence of regulatory and immunostimulatory DC subsets, supporting the emergence of the concept of toierogenic DCs (247) . Further, treatment with F]t3 ligand which is known to expand DCs in vivo, bas been reported to enhance oral tolerance (248) . Interestingly, LPS, whicb is known to cause the rapid exit of DCs, has also been shown to eniiance tolerance induction (249) . Tbis information places strong emphasis on tbe site of entry and on the intraceiiuiar patiiway of processing of antigens administered to a mucous membrane in the induction of tolerance and/or immunity and caiis for the need to deveiop vaccine formuia- The most striking observation in aii three modeis of autoimmune diseases tested was the fmding that treatment with CT-B-aiitigen suppressed ieukocyte infiitration into tbe target organ.

Tbis suggests that the mechanisms governing induction of toierance by feeding or inhaling CT-B-iinked antigens may involve modifications of tiie migratory beiiavior of infiammatory celis.

By coupling thymoeytes to cboiera B subunit and feeding this conjugate to mice, it has been possibie to significantiy prolong press botb systemic Tbi-and Th2-driven responses. The fact that the same type of regimen is aiso known to favor S-IgA responses in mucosal tissues makes this concept even more attractive since IgA is known to be non-phiogistic and couid theoreticaiiy outcompete IgF for binding to a given aiiergen.

However, it shouid aiso be pointed out tbat suppression of Th2driven responses such as IgE antibody responses appears considerabiy more difficult to achieve than corresponding Thi responses (e.g. DTH) in an animai aiready systemicaiiy sensitized to tiie aiiergen; in the iatter situation, mucosai treatment with CT-B-con jug ated aiiergen required proionged administration ofthe conjugate and was effective only with certain aiiergens (C. Rask, J. Holmgren, C. Czerkinsky, unpubhshed observations) .

Somew-hat surprisingiy. vaccinoiogists in general and mucosai immunoiogists in particular have usually believed that a recip-rocal relationship exists between induction of immunity and tolerance, Tbe observation tiiat mucosal immunity, whicb is typified by secretory IgA antibodies, may deveiop concomitantiy with systemic immunoiogicai toierance iias ied to liie behef that vaccines against mucosai pathogens shouid primariiy stimuiate immunity without inducing toierance. However, from a theoretical standpoint, tbe possibihty to manipuiate the mucosai immune system towards botb immunity and toierance appears rather attractive wben considering strategies aimed at protecting the host from coionization or invasion by mucosai pathogens but aiso to interfere witb the development of potentiaiiy harmfui systemic immunoiogicai reactions against the same pathogens or tiieir products, Tbe notion tbat immunoiogicai toierance may provide the iiost with a protective mechanism against an infectious disease (265) , are now being activeiy addressed.

Mucosaiiy induced toierance bas the virtue of being a powerfui naturai and specific protective mecbanism against adverse immune reactions tbat may resuit from mucosai intake of immunogenic matters. This property may be utiiized to treat disorders associated witii untoward immune responses to seif and non-seif antigens, sucb as certain autoimmune diseases, aiiergic reactions, and graft rejection (Table I) 

Cross-procection in mice infected with influenza A virus by ihe respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T-cell reactivity

Intraceliular neutraiization of virus by immunoglobulin A antibodies

The mucosal immune system

The development of imnionoglobulin levels in man

Appearance of secretory IgM and IgA antibodies to Escherichio coli in saliva during early infancy and childhood

Brandtzaeg P The role ol J chain and secretory component in receptor-mediaicd gianduiar and hepatic iransport of immunoglobulins in man

Selective transport of IgA: ceUuiar and molecular aspects

The mouse gut T lymphocyte, a novel type of T cell. Nature, origin, and traffic in mice in normal and graft-versus-host condidons

The early appearance of specific cytotoxic T cells in murine gut mucosa

Human intestbial mononaclear cells. I. Invesdgation of antibody-dependent, Iectin-induced and spontonaeous cell-media ted cytotoxic capabihties

Cytotoxic T cells iTi small intestine, epithelial, lamina propria and lung lymphocytes

Natural killer activity of gut mucosal lymphoid cells in mice

Functional characteristics of lymphocytes isolated from the rat large intestine. Response to T-cell mitogen and natural killer cell activity Gastroemerology I984

Leukocytes in tlie mtestinal epithelium: An unusual immunologic compartment

The relative role of lymphocyte granule exo cyto sis versus deathreceptor-mediated cytotoxicity in viral path o physiology

Gut mucosal immunization with reovirus serotype I/L stimulates virus-specific cytotoxic T cell precursors as well as IgA memory cells in Peyer's patches

Memory and distribution of virus-specific cytotoxic T lymphocytes (CTLs) and CTL precursors after rotavirus infection

CD8 lymphocyte subpopulations in Peyer's patches Induced by reovirus serotype i infection

Reovirus-induced liver disease in severe combined immunodeficient {SCID) mice. A model for the study of viral infection, pathogenesis, and clearance

Developmental relationship between cytotoxic a p T-cell-receptor-positive intraepithelial lymphocytes and Peyer's patch lymphocytes

The response oi" gut-associated T lymphocytes to intestinal viral immtuiization

Adoptive transfer of gut intraepithelial lymphocytes protects against murine infection with Toxoplasmo gondi

Rotavirus-sped fit cytotcixic T lymphocytes passiveiy protect against gastroenteritis in suckling mice

Immunization with bacuiovirUS-expressed recombinant rotavirus proteins VPl, VP4, VP6 and VP7 induces CD8*^ T lymphocytes that mediate clearance of chronic rotavirus infection in SCID mice

Evidence for CD8* T-cell immunity to murine rotavirus in the absence of perforiii, fas and Y interferon

Protective effect of rotavirus VP6-specific IgA monoclonal antibodies ihat lack neutraliziaig activity

Mucosal immunization with HIV-] peptide vaccine induces mucosal and systemic cyiotoxic T lymphocytes and protective immunity in mice against intrarectal recombiTiant HIV-vaccinia challenge

The role of host responses in the recovery of mice from Sendai virus infection

Respiratory syncytial virus infection in cydophosphamjde-treated cotton rats, Infeci Immun I 982

Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge

Host responses to respiratory virus infection and immunization

Cellular events in the lymph node and lung of mice with influenza

Clearance of influenza virus respiratory infectiou in mice lacking class I major histocompatibility complex-restricted CDS* T cells

Respiratory syncytial virus infection in C57BL/6 mice: Clearance of virus from the lungs with virus-,specific cytotoxic T cells

Cytotoxic T cell activity against the 22-kDa protein of human respiratory syncytial virus (RSV) is associaced with a significant reduction in pulmonary RSV replicadon

Role of T lymphocyte subsets in the pathogenesis of primary infeciion and rechallenge with respiratory syncytial virus in mice

Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus

Mucosal transmission of simian immunodeficiency virus

Antiviral cyiotoxic T lymphocytes in vaginal mucosa of simian immunodeficiency virusinfected rhesus macaques

Rhesus macaques previouslyinfected with simian /human immunodeficiency virus are protected from vaginal challenge with pathogenic SIV

HlV-1 induces cytotoxic T lymphocytes in the cervix of infected women

Lymphocyte homing and homeostasis

Distinct regulation of lymphokine production is found In fresh versus in vi[ro primed murine helper T cells

Frequencies of IL-2-and IL-4-secreting T cells in naive and antigen-stimulated lymphocyte populations

Regulation of murine lymphokine productiou in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function

Development of Th I CD4' T cells through IL-12 produced by Listeria-induced macrophages

Interleukin-12: A proinflammatory cytokine with immimoregulatory functions that bridge innate resistance and anti gen-specific adaptive immunity

Interferon-y and B cell stimulatory factor-1 reciprocally regulate Ig isotype production

CD4"NK1.1+ T cells promptly produce interleukin 4 in response to ill vivo challenge with anti-CD3

Role of NK 1.1 • * T cells in a Th2 response and in immunoglobulin E production

Role of cytokines in the differentiation of CD4+ T-cell subsets in vivo

The role of helper T-cell products in mouse B-ce!l differentiation and isotype regulation

Thl and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties

Acquisition of lymphokine-producing phenorype by CD4'' T cells

Lymphokine control of in vivn immunoglobulin isotype selection

Immunoglobulin ciass switching; Molecular and cellular analysis

kinsky et al • Mucosdl vaccines

Anti-proliferative effect of IFN-yin imtnune regulation, I, IEN-y inhibits the proiiferadon of Th2 but not Th 1 murine helper T-lymphocyte clones

Detection of human cytokine-secreting cells in distinct anatomical compartments

The freqtiency of celis secreting inierferon 7, IL-4, IL-5 and IL-10 in the blood and duodenal mucosa of children with cow's milk hypersensitivity

Regulation of mucosal and systemic antibody responses by T helper ceU subsets, macrophages and derived cytokines following oral immunization with live recombinantSalnionclIa

Reguiadon of IgA synthesis and immune response by T cells and interleukins

10 and transforming growth factor b cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A

Transforming growth factor-b directs IgA switching in human B cells

Interleukin 5 and interleukin 4 produced by Peyer's patch T cells selectively enhance immunoglobulin A expression

Bond MW A mouse T-cell product that preferentiaUy enhances IgA production

Murine Peyer's patch T-cell clones: characterization of antigen-specific helper T cells for immuno glob til in A responses

Isotype-specificity of helper T-cell clones: Peyer's patch Th cells preferentially collaborate with maiure IgA B cells for IgA responses

Transforming growth factor beta specifically enhances Ig.^ production by lipopolysaccharide-stimulaied murine B lymphocytes

Transforming growth factor-P 1 is a costimulaior for IgA production

Regulatory T-cel! clones induced by oral tolerance: suppression of autoimmune encephalomyelitis

Oral tolerance: immune mechanisms and treatment of autoimmune diseases

Oral tolerance to myelin basic protein and natural recovery from experisnental autoimmune encephalomyelitis are associated with down regulation of inflammatory cytokuies and differential upreguiation of TGI'-P, IL-4 and PGE expression in the brain

JJ Peyer's patches: an enriched source of precursors Ibr IgAproducing immunocytes in the rabbit

Organ and isoiype disiribution of plasma cells producing specific aniibody after oral immunizaiion: evidence for a generalized secretory immune system

HameleersDM. Stoop AE, van der Ven I. Biewenga J. van der Baan S, Sminia T Intraepithelial lymphocytes and non-lymphofd cells in the human nasal mucosa

Immunohistochemical characterization of intraepithelial and subepithelial mononuclear cells of ihe upper airways

115, vanderVenI,SminiaT. The development and structure of mouse nasal-associated lymphoid lissue: an immnno-and enzymehisiochemical suidy

Effect of lonsillectomy and adenoidectomy on nasopharyngeal antibody response lo poliovirus

Langerhans'cells and lymphocyte subsets in the female genital tract

Expression and gene transcript of Ec receptors for IgG, HLA class II antigens and Langerhans cells in human cervico-vaginai epithelium

The distribution of immtmocompetent cells in ihe genital tract of HIV-positive women

Secretory immune system in the female reproductive tract: I. Immunoglobulin and secretory component-containing celb

Secretory immuniiy in the female reproductive tract

Loca! antibody response lo po!iovaccine in the fema!e genita! tract

Mucosal immtmity in the female genital trace: relevance to vaccination efforts against the human immunodeficiency virus

Pohl W Antibody in tears, saliva and nasal secretions following oral immunization of humans with inactivated influenza virus vaccine

Oral immunization wit!i influenza virus: Experimenia! and chnical studies

Human immune responses to influenza virus vaccines administered by systemic or mucosal routes

Compans RW Mucosal immunization against influenza virus using bioadhesive polymers. Proceedings, Options for the Control of Influenza III

Qerkinsky et al • Mucosal vaccines 1 29. Gizurarson G, Jonsdottir VM. Heron I. Intranasal administration of diplheria toxoid, Seiecting antibody isoiypes using formulations having various lipophilic characterislics

Antigen delivery systems: new approaches to niacosal immunizaiion

Handbook of mucosa! iti

Lipid mairix-based subunil vaccines: a structure-function approach to oral and parenteral immunization

Vaccine containing biodegradable tnicrospheres specifically enter ihe gutassociated lymphoid tissue foUowing oral administration and induce a disseminated mucosal immune response

Targeting and controUed release of aniigens for die effective induction of secretory antibfidy responses

Current options for vacciiie dehvery systems by mucosa! routes

Cholera loxin B subunit as a carrier protein to sdmulate a mticosal immune response

Oral vaccination. Ideniificaiion of classes of proteins that provoke an inunune response upon ora! tending

Oral administration ofa streptococca! antigen coup!ed to cholera toxin B subunit evokes strong antihody responses in salivary glands and extramucosal tissues

Local and systemic responses to dextraii-cholera toxin B subunit conjugates

Comparative effectiveness ofthe cholera toxin B subunit and alkaline phosphatase as carriers for oral vaccines

Recombfnant systetn for overexpression of cholera toxin B subunit in Vibrio thoierae as a basis for vaccine development

Fusion proteins containing tlie A2 domain of cholera toxin assemble with B polypeptides of cholera toxin to form immunoreaciive and ftiiictional holoioxin-iike clumcras

Mucosal immunization with a bacterial protein antigen genetically coupled to cholera toxin A2/B subunits

Mucosal immunogenicity ofa holotoxin-like molecti!e containing t!ie serinc-rich Entamoeba hi^lolytica protein (SREHP) fused to the A2 domain of cholera toxin

Applications of molecular microbiology to vatcinology

Vaccination in the 21st century

Live oral aviritlcnt Salmoneilu vaccines

Attenuated Sfllmonella as vectors for oral immunization

The development of oral vaccines based on live attenuated SulmoncNo strains

Sulmonellfl as carriers of heteroiogous antigens

Sdlmondlu as oral vactint carriers

SnlmonelJo typlii vaccine strain CVD 908 exprt'.ssing the circumsporozoite protein of Plasm oil itim fulcipartitn: strain construction and safety about immunogen icily in humans

Oral Sulmonelia typhimunum (AroA ) vaccine expressing a major leishmania! stJiface protein (gp 63) preferentially induces T helper 1 cell's and protective immunity against !eish manias is

Oral imiiuini/Jtion of inrerleukin-4 (IL-4) knockout mice with a recombinant Sulmuntllo strain or cholera toxin reveals that CD4* Th2 cells producing IL-6 and IL-10 are associated with mucosil immunogiohuiin A responses

Recoinbinant vaccine delivery systems and encoded vaccines

Induction of mucosal immune responses against a lietero!ogoiis antigen fused to filamentous hemagglutinin aiier intranasal immunizati.on with recombinant Bordetdia p£rlti«l5

Use of human adenovirus-based vectors for antigen expression in animals

Adenoviruses as gene-deliva7 vehic!es

Characterization ofa human cell line transformed by DNA from Iiuman adenovirus type 5

Long-term immunity and protection against herpes simplex virus type 1 in the murine female genital tract after mucosal but noi s>'stemic Immunization

Long-lived cytoioxic T lytnphocyte memory in mticosai tissues after mucosal but noi systemic immunization

^n adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal imnume responses in rhesus tnacaques and decreases viral burden following vaginal challenge

Czertcinsky et al -Mucosal vaccines

A recombinant human adenovirus vaccine against rabies

Immunogenicity of recoinbinant adenovirui-respiraiory syncytial virus vaccines with adenovirus types 4, 5 and 7 vectors in dogs and a chimpanzee

Induciion of mucosal immunity in cotton rats lo haemagglutinin-esterase glycoprotein of bovine coronavirus by recombinant adenovirus

Repetitive adenovirus administration lo the parotid gland: role of fmmunological barriers and induction of tolerance

Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine

Expression of rabies virus glycoprotein from a recoinbinant vaccinia virus

Enteric immunizaiion of mice againsi influenza wiih recombinant vaccinia

Interleukin-5 expressed by a recombfnant virus vector enhances specific mucosal IgA responses in vivo

Applications of poxvirus vectors to vaccination: an update

Mucosal vaccination with recombinant poxvirus vaccines protects ferrets against symptomatic CDV infection

Comparison of the efficacy of replicationdefective adenovirus and Nyvac poxvirus as vaccine vectors in mice

Vaccination against pox diseases under immunosuppressive conditions

A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus

Moldoveatni 7, Recombinant viruses as vectors for mucosal immuniiy

Humoral, mucosal, and cellular immuniiy in response to a htiman immunodeficiency virus lype 1 immunogen expressed by a Venezuelan equine encephahiis virus vaccine vector

A viral vaccine vector that expresses foreign genes in lymph nodes and protects againsi niucosal challenge

Smith JR Repiicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heteroiogous genes in vitro and immunization against heterologoits pathogens in vivo

Toward a poliovirus-based simian immunodeficiency virus vaccine: correlation beiween genetic stability and i m muno gem ciiy

Characierization of the expression and immunogeniciiy of poliovirus replicons that encode simian immunodeficiency virus SIVmac239 Gag or envelope SU proteins

Direct gene transfer into mouse muscle in vivo

Heteroiogous protection against influenza by injection of DNA encoding a viral protein

Unique palindromic sequences in synthetic oligonucleotides are required lo induce lEN and augment lEN-mediated natural killer activity

Immunostimulatory DNA sequences necessary for effective intradermal gene immunizaiion

CpG motifs in bacterial DNA trigger direct B-cell activation

CpG motifs preseni in bacteria DNA rapidly induce lymphocytes to secrete ititerieukin 6, interleukin 12, and interferon

Harty JT CpG DNA induces sustained IL-1 2 expression in vivo and resistance to Listma monocytogenes challenge

Activation of cutaneous dendritic cells by CpG-containing oligonucleo tides: a role for dendritic cells in the augmentation of Th I responses by immunostimulatory DKA

CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus

DNA vaccines: protective immunizations by parenteral, mucosal and gene-gun inoculations

Gene inoculation generates immune responses against HIV-1

Induction of mucosal immunity against herpes simplex virus by plasmid DN.' immunization

Baragazzi ML, el al. Safety and immunogenicity of intramuscular and intravaginal dehvery of HIV-1 DNA constructs to infant chimpanzees

Intranasal immunization ofa DNA vaccine with IL-1 2-and graiiulocytemacrophage colony-stimulating factor (GM-CSF)-expressing piasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens

Comparison of intranasal and intramuscular immuni:ialion against human immunodeficiency virus type 1 with a DNAmonophosphoryl lipid A adjuvant vaccine

Intranasal immunization with plasmid DNAlipid complexes elicits mucosal immunity in the female genital and rectal tracts

Oral delivery of micro-encapsulated DNA vaccines

Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles

Oral somatic transgene vaccination using attenuated S. typhimurium

Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimuriura, results in protective immunity againsi a murine fibrosarcoma

Antigen presentation by dendrilic cells after immunization with DNA cncoditig a major histocompaiibilit)' complex class Il-restricted viral epitope

Specific immune induction following DNA-based immunization through in vivo iransfeciion and aciivation of macrophages

DNA vaccination: transfection and activation of dendritic cells as key events for immunity

Expression of hepatitis B surface andgen in transgenic plants

Oral vaccine production in the edible tissues of transgenic plants

Steinman RM. Dendritic cells and the control of immunity

Bone marrow-derived dendritic cells serve as poieni adjuvants for peptide-based antiiumor vaccines

Dendritic cell vaccines for cancer immunotherapy

Inactivated influenza virus, when presented on dendritic ceils, elicits human CD8+ cytolytic T-celi responses

Burrcliu burgdorferi-pulsed dendritic cells induce proieciive immtnie response against tick transmitted spirochetes

Virus-mediated delivery of antigenic epitopes into dendrilic cells as a means to induce CTL

Portis JCp Caldweil HD. Vaccination against chlamydial genital iract infection afier immimisation with dendritic cells pulsed with nonviable chlamydiae

Structure and function of cholera toxin and the related Escherichia coli he a I-labile enterotoxin

Ginsburg V Comparison ofthe carbohydraie-binding specificities of cholera loxin and Escherichia coii heat-labile enierotoxins LTh-I. LT-IIa, and LT-IIb

Cholera toxin did not induce oral toierance in mice and abrogated oral tolerance lo an unrelated antigen

Strong adjuvant properties of cholera loxin on gui mucosa! immune responses to orally presented antigens

Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to tmrelated protein antigens

Helper T-cell subsets for immunogiobuhn A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues

Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4

Production of IgE antibody and aliergic sensitization of intestinal and peripheral tissues after oral immunization with protein Ag and cholera toxin

The in vtiro production of cytokines by mucosai lymphocytes immunized by oral administration of key-hole limpei hemocyanin using cholera toxin as an adjuvant

Cholera toxin B subunit: an effective transiiiucosal carrier delivery system for induction of peripheral immunological tolerance

Cholera toxin acts as a potent adjuvant for the induction of cytotoxic T-lymphocyte responses with non-replicating antigens

The adjuvant effect of Vibrio choieme and Escherichia coli heatlabiie enterotoxins is linked to their ADPribosyltransferase activity

Mechanisms for mucosal immunogeniciiy and adjuvancy of Escherithia coli labile enteroioxin

Mutants of Escherichia coll heatlabile loxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants

Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity

A nontoxic mutant of cholera loxin elicits Th2-type responses for enhanced mucosal immuniiy

Mutants in ihe ADPribosyltransfera.se cleft of cholera toxin lack diarrhoeagenicity but retain adjuvanticity

Immuiiological Kevievvs i70/l999

Czerkinsk/ et al -Mucosal vaccines

Systemic tolerance and secretory immuniiy after oral immunization

The role of chemokines in oral loierance: abrogation of nonresponsiveness by ireatment with anti-MCP-1

Immunological responses to fed proiein antigens in mice, II Oral tolerance for CMI is due to activation o( cyclopliosphamide-sensitive cells by gulprocessed antigen

Anligen trafficking in the intestine

The intestinal epithelial cell: a non conventional type of antigen-presenting cell

Small B cells as antigenpresenting cells in the induction of tolerance to soluble protein aniigens JExpMed

Dendritic cells and Langerhans cells in the uptake of mucosal antigens

Resting respiratory tract dendritic cells preferentially stimulate T helper cell type 2 responses and require obligatory cytokine signals for induction of Thl immunity JExpMed

Dendritic cells and tolerance induction

Expanding dendritic cells in vivo enhances the induction of oral tolerance

Suppression o( experimental autoimmune encephalomyeliiis by oral administration of myehn basic protein. III. Synergistic effect of Iipopolysaccharide

Chnical and immtmological response to oral and subcutaneous iramunotherapy with grass pollen extracts. A prospective study

Oral hyposensitizadon of children with poliinosis or house dust asthma

Inhibition of T cell and antibody responses lo house dust mite allergen by inhalation ofthe dominani T cell epitope in naive and sensiiiicd mice

Inhibition of specific immune responses by feeding protein antigens. II. Effects of prior passive and active immunization

Arthritis: animal models of oral tolerance

Cholera toxin B subunit as transmucosal carrier-deli very and immunomod tliat ing system for induction of anti-infectious and anti-pathological immuniiy

Treatment of experimental autoimmune arthritis by nasal administration of a type il collagen-cholera toxoid cotijtigaie vaccine

A cholera toxoid-Insulin conjugate as oral vaccine against spontaneous autoimmune diabetes

Conditions affecting enhanced corneal allograft survival by oral immunization

Kuraia T Suppression of delayed-type hyper sensitivity and IgE antibody responses lo ovaibumin by intranasal administration of Escherichifl coli heat-labile enicroioxin B subunit-conjugated ovaibumin

Resistance to Lei. sKmanio niajof induced by tolerance to a single antigen

SunJB, etal, Intranasal administration of a Schistosomd manioni gluiathione S-transferasecholera toxoide conjugate vaccine epokes aniiparasilic and antipathological immunity in mice

Huang SK, Leong KW Oral gene delivery wiih chitosan-DNA nanoparticks generates immunologic protection in a murine model of peanut allergy